|Articles|December 5, 2014
Innocutis has launched its newest product, Sitavig
Advertisement
INNOCUTIS has launched its newest product, Sitavig (acyclovir) 50 mg buccal tablets. Sitavig uses Lauriad technology, which consists of a tablet that sticks to the gum, above the canine tooth on the side of the lip that is infected with a cold sore, according to the company. This white- to slightlyyellow tablet is tasteless and odorless. It dissolves to provide a sustained release of medicine.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
The SkinCARE Questionnaire: Assessing the Psychological Dimensions of Skin Health Beyond Disease
5














